Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Arjun V. Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia, Nancy A. Dawson, Michiel S. Van Der Heijden, Robert Dreicer, Sandy Srinivas, Margitta M. Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. QuinnIgnacio Duran, David R. Shaffer, Bernhard J. Eigl, Petros D. Grivas, Evan Y. Yu, Lei Shi Li, Edward E. 3rd Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thastrom, Oyewale Abidoye, Gregg D. Fine, Dean F. Bajorin

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.'. Together they form a unique fingerprint.